Literature DB >> 7694427

[The peptide mapping of the E2-2 and E2-6 sites of the E2 glycoprotein in the Venezuelan equine encephalomyelitis virus].

V A Sviatchenko, A V Pereboev, E V Agapov, I A Razumov, A N Sabirov, G A Mizenko, V V Samukov, V B Loktev.   

Abstract

Nine peptides were synthesized for detailed mapping of VEE virus E2-2 and E2-6 sites responsible for the formation of protective antibodies that neutralize the virus and block hemagglutination. The sequence of the peptides over-lapped the regions of amino acid residues 30-75 and 202-250 of VEE virus E2 protein in which antigenic mutations caused by monoclonal antibodies to E2-2 and E2-6 sites had been mapped. None of the synthesized peptides reacted in the enzyme immunoassay with a panel of 17 Mabs to VEE virus E2 protein. However, eight peptides reacted with polyclonal antiviral serum and two of them elicited antiviral antibody production. The E2-2 site might be associated with amino acid residues 30-45, and the region of E2 residues 57-62 in which antigenic mutations are observed is not a linear type antigenic determinant, but participates in the formation of antigenic determinants of the conformational type. The mapping of residues 202-250 demonstrated that all the peptides in this region were well recognized by polyclonal antiviral serum. The residues 235-240 were shown to form a linear epitope which provided a crossover between VEE and EEE viruses and was not recognized by 19 types of monoclonal antibodies cross-reacting with VEE and EEE viruses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694427

Source DB:  PubMed          Journal:  Vopr Virusol        ISSN: 0507-4088


  2 in total

1.  Localization of four antigenic sites involved in Venezuelan equine encephalomyelitis virus protection.

Authors:  E V Agapov; I A Razumov; I V Frolov; A A Kolykhalov; S V Netesov; V B Loktev
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  Glycoproteins E2 of the Venezuelan and eastern equine encephalomyelitis viruses contain multiple cross-reactive epitopes.

Authors:  A V Pereboev; I A Razumov; V A Svyatchenko; V B Loktev
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.